These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

169 related items for PubMed ID: 9717816

  • 21. Therapeutic potential of curcumin in human prostate cancer. II. Curcumin inhibits tyrosine kinase activity of epidermal growth factor receptor and depletes the protein.
    Dorai T, Gehani N, Katz A.
    Mol Urol; 2000; 4(1):1-6. PubMed ID: 10851300
    [Abstract] [Full Text] [Related]

  • 22. 20-Cyclopropyl-cholecalciferol vitamin D3 analogs: a unique class of potent inhibitors of proliferation of human prostate, breast and myeloid leukemia cell lines.
    Koike M, Koshizuka K, Kawabata H, Yang R, Taub HE, Said J, Uskokovic M, Tsuruoka N, Koeffler HP.
    Anticancer Res; 1999; 19(3A):1689-97. PubMed ID: 10470102
    [Abstract] [Full Text] [Related]

  • 23. Suppression of human prostate cancer cell growth by ciprofloxacin is associated with cell cycle arrest and apoptosis.
    Aranha O, Grignon R, Fernandes N, McDonnell TJ, Wood DP, Sarkar FH.
    Int J Oncol; 2003 Apr; 22(4):787-94. PubMed ID: 12632069
    [Abstract] [Full Text] [Related]

  • 24. Restoration of bax in prostate cancer suppresses tumor growth and augments therapeutic cell death induction.
    Honda T, Gjertsen BT, Spurgers KB, Briones F, Lee SJ, Hobbs ML, Meyn RE, Roth JA, Logothetis C, McDonnell TJ.
    Anticancer Res; 2001 Apr; 21(5):3141-6. PubMed ID: 11848465
    [Abstract] [Full Text] [Related]

  • 25. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
    Traxler P, Allegrini PR, Brandt R, Brueggen J, Cozens R, Fabbro D, Grosios K, Lane HA, McSheehy P, Mestan J, Meyer T, Tang C, Wartmann M, Wood J, Caravatti G.
    Cancer Res; 2004 Jul 15; 64(14):4931-41. PubMed ID: 15256466
    [Abstract] [Full Text] [Related]

  • 26. Mixed-lineage kinase inhibitors require the activation of Trk receptors to maintain long-term neuronal trophism and survival.
    Wang LH, Paden AJ, Johnson EM.
    J Pharmacol Exp Ther; 2005 Mar 15; 312(3):1007-19. PubMed ID: 15525794
    [Abstract] [Full Text] [Related]

  • 27. 2-Methoxyestradiol induces G2/M arrest and apoptosis in prostate cancer.
    Qadan LR, Perez-Stable CM, Anderson C, D'Ippolito G, Herron A, Howard GA, Roos BA.
    Biochem Biophys Res Commun; 2001 Aug 03; 285(5):1259-66. PubMed ID: 11478793
    [Abstract] [Full Text] [Related]

  • 28. Expression of adrenomedullin and peptide amidation activity in human prostate cancer and in human prostate cancer cell lines.
    Rocchi P, Boudouresque F, Zamora AJ, Muracciole X, Lechevallier E, Martin PM, Ouafik L.
    Cancer Res; 2001 Feb 01; 61(3):1196-206. PubMed ID: 11221851
    [Abstract] [Full Text] [Related]

  • 29. Vitamin D inhibition of prostate adenocarcinoma growth and metastasis in the Dunning rat prostate model system.
    Getzenberg RH, Light BW, Lapco PE, Konety BR, Nangia AK, Acierno JS, Dhir R, Shurin Z, Day RS, Trump DL, Johnson CS.
    Urology; 1997 Dec 01; 50(6):999-1006. PubMed ID: 9426741
    [Abstract] [Full Text] [Related]

  • 30. The novel antimicrotubule agent cryptophycin 52 (LY355703) induces apoptosis via multiple pathways in human prostate cancer cells.
    Drew L, Fine RL, Do TN, Douglas GP, Petrylak DP.
    Clin Cancer Res; 2002 Dec 01; 8(12):3922-32. PubMed ID: 12473608
    [Abstract] [Full Text] [Related]

  • 31. A novel hydroxamic acid compound, BMD188, demonstrates anti-prostate cancer effects by inducing apoptosis. I: In vitro studies.
    Li L, Zhu Z, Joshi B, Porter AT, Tang DG.
    Anticancer Res; 1999 Dec 01; 19(1A):51-60. PubMed ID: 10226524
    [Abstract] [Full Text] [Related]

  • 32. Tyrphostin AG825 triggers p38 mitogen-activated protein kinase-dependent apoptosis in androgen-independent prostate cancer cells C4 and C4-2.
    Murillo H, Schmidt LJ, Tindall DJ.
    Cancer Res; 2001 Oct 15; 61(20):7408-12. PubMed ID: 11606371
    [Abstract] [Full Text] [Related]

  • 33. Constitutive activation of the 41- and 43-kDa mitogen-activated protein (MAP) kinases in the progression of prostate cancer to an androgen-independent state.
    Oka H, Chatani Y, Kohno M, Kawakita M, Ogawa O.
    Int J Urol; 2005 Oct 15; 12(10):899-905. PubMed ID: 16323984
    [Abstract] [Full Text] [Related]

  • 34. In vitro and in vivo effects of bicalutamide on the expression of TrkA and P75 neurotrophin receptors in prostate carcinoma.
    Festuccia C, Gravina GL, Muzi P, Pomante R, Ventura L, Ricevuto E, Vicentini C, Bologna M.
    Prostate; 2007 Sep 01; 67(12):1255-64. PubMed ID: 17596848
    [Abstract] [Full Text] [Related]

  • 35. Therapeutic potential of curcumin in human prostate cancer. III. Curcumin inhibits proliferation, induces apoptosis, and inhibits angiogenesis of LNCaP prostate cancer cells in vivo.
    Dorai T, Cao YC, Dorai B, Buttyan R, Katz AE.
    Prostate; 2001 Jun 01; 47(4):293-303. PubMed ID: 11398177
    [Abstract] [Full Text] [Related]

  • 36. Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers.
    Xu Y, Dalrymple SL, Becker RE, Denmeade SR, Isaacs JT.
    Clin Cancer Res; 2006 Jul 01; 12(13):4072-9. PubMed ID: 16818707
    [Abstract] [Full Text] [Related]

  • 37. A radioactive binding assay for inhibitors of trkA kinase.
    Knight E, Connors TJ, Maroney AC, Angeles TS, Hudkins RL, Dionne CA.
    Anal Biochem; 1997 May 01; 247(2):376-81. PubMed ID: 9177701
    [Abstract] [Full Text] [Related]

  • 38. Tyrosine kinase inhibitor emodin suppresses growth of HER-2/neu-overexpressing breast cancer cells in athymic mice and sensitizes these cells to the inhibitory effect of paclitaxel.
    Zhang L, Lau YK, Xia W, Hortobagyi GN, Hung MC.
    Clin Cancer Res; 1999 Feb 01; 5(2):343-53. PubMed ID: 10037184
    [Abstract] [Full Text] [Related]

  • 39. SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors.
    Laird AD, Vajkoczy P, Shawver LK, Thurnher A, Liang C, Mohammadi M, Schlessinger J, Ullrich A, Hubbard SR, Blake RA, Fong TA, Strawn LM, Sun L, Tang C, Hawtin R, Tang F, Shenoy N, Hirth KP, McMahon G, Cherrington.
    Cancer Res; 2000 Aug 01; 60(15):4152-60. PubMed ID: 10945623
    [Abstract] [Full Text] [Related]

  • 40. The novel Trk receptor tyrosine kinase inhibitor CEP-701 (KT-5555) exhibits antitumor efficacy against human pancreatic carcinoma (Panc1) xenograft growth and in vivo invasiveness.
    Miknyoczki SJ, Dionne CA, Klein-Szanto AJ, Ruggeri BA.
    Ann N Y Acad Sci; 1999 Jun 30; 880():252-62. PubMed ID: 10415871
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.